Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
|Articles|August 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 8
- Volume 5
- Issue 8
Diagnostic Test for H pylori
TUSTIN, Ca--AMDL, Inc. has filed a 510(k) Premarket Notification with the FDA for PyloriProbe, its diagnostic test for the detection of Heli-cobacter pylori. This bacterium is associated with chronic gastritis and gastric and duodenal ulcers, and has been classified by WHO as a class I carcinogen that increases the risk of developing stomach cancer. Pylori-Probe is a direct enzyme immunoassay (EIA) that detects the presence of H pylori antibodies in serum samples.
Advertisement
TUSTIN, Ca--AMDL, Inc. has filed a 510(k) Premarket Notificationwith the FDA for PyloriProbe, its diagnostic test for the detectionof Heli-cobacter pylori. This bacterium is associated withchronic gastritis and gastric and duodenal ulcers, and has beenclassified by WHO as a class I carcinogen that increases the riskof developing stomach cancer. Pylori-Probe is a direct enzymeimmunoassay (EIA) that detects the presence of H pyloriantibodies in serum samples.
Articles in this issue
about 30 years ago
Chemo Improves Pain Relief in Advanced Prostate Cancerabout 30 years ago
NCCR Urges Congress to Support Senate Bill for Cancer Researchabout 30 years ago
Researchers Propose New Treatment Guidelines for HIVabout 30 years ago
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Andersonabout 30 years ago
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samplesabout 30 years ago
New Thinking on HIV Progression Leads to New Strategiesabout 30 years ago
Hospitals Told Not to Capitate for 'Wrong' Reasonsabout 30 years ago
More Study Needed of Possible Carcinogenesis of Winter Gas Additiveabout 30 years ago
President Makes NCAB AppointmentsAdvertisement
Related to this article
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5